Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. - Wikidata - wikimedia - TriplyDB

Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV.

Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV.

http://www.wikidata.org/entity/Q36835221

about

Influence of immunoglobulin isotype on therapeutic antibody function Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.Macrophages eliminate circulating tumor cells after monoclonal antibody therapy The roles of regulatory B cells in cancer Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma.CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice.Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment.Toll-like Receptor 4 Ligands Down-regulate Fcγ Receptor IIb (FcγRIIb) via MARCH3 Protein-mediated Ubiquitination.Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial.Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanisms Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function.Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity.Neutrophils mediate antibody-induced antitumor effects in mice.Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines.Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies.Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy Anti-CD20 monoclonal antibodies: historical and future perspectives.Evolution of anti-CD20 monoclonal antibody therapeutics in oncology.Sensitizing protective tumor microenvironments to antibody-mediated therapy.B-lymphocyte effector functions in health and disease.Modulation of tumor immunity by therapeutic monoclonal antibodies.New antibody drug treatments for lymphoma.Mechanisms of action of CD20 antibodies.FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer.CTLA-4 Limits Anti-CD20-Mediated Tumor Regression.The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma.B Cells with Regulatory Function in Animal Models of Autoimmune and Non-Autoimmune Diseases Mouse and human FcR effector functions.bIgG time for large eaters: monocytes and macrophages as effector and target cells of antibody-mediated immune activation and repression.FcγR requirements leading to successful immunotherapy.Structural analysis of Fc/FcγR complexes: a blueprint for antibody design.The prognostic role of CD68 and FoxP3 expression in patients with primary central nervous system lymphoma.Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcγ receptors on macrophages.

P2860

Q26772080-552183A9-79E6-4F16-B05D-75D321CFB27E Q28069362-352EFE6F-FE05-4235-9A31-B1C2CA579A9C Q28658712-107D03F3-9327-40E3-A042-541F71FC3DF3 Q30500362-F75A7D75-DC15-4817-8F84-18AA783F8AC2 Q30569758-82D0D97D-77A2-4D93-9A2D-18261E212D32 Q33765986-23D88FB1-1DE0-4FE5-932F-7A852D76F552 Q34212528-A4FD4996-9CE7-4B31-8546-C40F1795CC17 Q34707604-60D40900-92EE-4D2C-B788-3359F8C0D9D4 Q35220644-60F77A24-AB60-4AC8-9B4D-A6D88ACFC9E3 Q35484992-676EA567-2C6A-44E6-917E-BC462A4F44C2 Q36213431-08D4FE0C-CF4D-497D-93E3-90B4DE11D76D Q36455017-DA44547B-0E77-4C53-AA9D-0FEF3BB07F65 Q36594664-DCFDA066-29F4-4DDE-878F-65B0BEF993F4 Q36715971-DA2982F2-BEB9-490D-AED4-A40DB1AC8BB6 Q36800456-2D577315-980B-4476-A997-48BE034438EB Q37091230-CAC039E7-440B-428D-819D-6CA24C12A034 Q37222143-3E8188A3-562D-4E63-8E45-C398E2B815D0 Q37272029-ECB1B6C2-8A71-440D-A450-66778D5940DA Q37379398-78DAD5D7-6B87-4F85-83BC-B31E141AAC84 Q37468539-028E54EF-65F3-40EB-B77A-68DF703393F9 Q37535232-482ED711-94B0-446B-A4A8-4EC97891B802 Q37592814-98C1F3D8-2D25-4805-AD79-1439F3ED5EF6 Q37601775-2DABE082-A4E4-40A5-A5EA-89797BDED440 Q37676785-E047BF66-18E3-4C75-BDBF-6148A5543DA5 Q37683676-2DBBADC2-BCEE-4899-BCA4-65E23A6C5217 Q37815038-7151D985-5D23-43DF-9C17-DB56254F7C4E Q37832438-1AFE6A1B-6B34-44E2-9D5F-35DD658A9808 Q37852003-17F1594D-F4F9-4444-8A68-D53C0DFCD834 Q38066195-8EFDBBBC-0652-4E4B-A35F-1E4583806D81 Q38094625-CF957DE1-C5F0-4C68-8E71-8463BCBCCBF2 Q38291696-10CDB032-C728-4A90-BECB-D83E8926D663 Q38413093-50EC0E81-5ECC-4B5D-BEDC-94F117B30637 Q38530254-8E226A33-063B-4953-ACD8-625FC04CFE9B Q38559547-98A2C4B7-CD51-442E-BCAC-7C1622FF2AE3 Q38615349-1BDCC8C4-B296-4387-92DC-F43820D2D0B2 Q38615353-642E4639-787F-46E6-BD35-A29798F02E9B Q38615360-AEA7CA0D-C453-49C8-8164-272C20065D33 Q38615376-5A42B4F9-BB9B-4DCD-9F7F-BBC94CA5EC2E Q38784265-03BE4A38-6A28-48AE-9348-4645C082E74B Q38896842-6BBD7EC8-4711-4C18-A854-12955EF0F2B3

P2860

Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV.

http://www.wikidata.org/entity/Q36835221

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Lymphoma depletion during CD20 ...... , FcgammaRIII, and FcgammaRIV.

@en

type

label

Lymphoma depletion during CD20 ...... , FcgammaRIII, and FcgammaRIV.

@en

prefLabel

Lymphoma depletion during CD20 ...... , FcgammaRIII, and FcgammaRIV.

@en

P1433

Q36835221-8C92E0BC-925E-4FD7-87F1-50C48A0BB9D1

P1476

Q36835221-A2F7BD4D-8103-4D2D-883D-EFCF29F3D4B1

P2093

Q36835221-3F963C48-9478-403D-AE94-6493CB4CABFD

Q36835221-45CD7D99-2EE2-4E2D-BB62-9D363117028D

Q36835221-5135A021-8B1F-47FD-B256-70C4D810B005

Q36835221-7062AEDC-C68E-4DB4-AC84-2C11C8EF43A2

Q36835221-72240FBE-C3FA-4C0B-AFA9-74D4E77847D9

Q36835221-92DECF12-EE87-4878-A6DF-65A40E8FCECE

Q36835221-AF210E97-F830-4027-B4C6-7B7ABFDAE5B1

Q36835221-FCDC28C1-D34B-44B8-88C9-9B9162B2F810

P2860

Q36835221-06D1CF2B-4492-44BE-ADF1-5991A4E55943

Q36835221-0E243D5C-6F9F-4446-B41D-C7A7BF4802DA

Q36835221-11742AF9-B312-4BD6-A790-28D055FA7742

Q36835221-145D90CD-AC93-4CBE-B5CD-63BBAE9848D5

Q36835221-18EDB651-8ED0-40D7-A9CD-E7B2FC928B99

Q36835221-1B8EEFF9-6FE5-45BD-9323-6DC38CA09E62

Q36835221-1DA41BDD-998B-41D2-8ED6-7EAA15088FAD

Q36835221-2DFCA420-8974-4D4C-82CE-7EDB852561C5

Q36835221-3D2D6B76-93C1-44A3-BEB8-2A96E0D858D0

Q36835221-4ADFC9E4-B7B6-46F6-ACF9-71C0823A4FD8

P304

Q36835221-DDFAAB82-49F8-41A8-910E-45A95349743F

P31

Q36835221-A6330FFE-7DA6-4B82-B339-46B067875C7F

P356

Q36835221-DEE86C64-81A1-4DB4-A97D-88D43BE8522D

P407

Q36835221-FB3C4583-D5B5-48BF-A0B3-9141BCCBEC7A

P433

Q36835221-806ADF99-5D84-45CC-A37D-E5E82F2C2AD5

P478

Q36835221-F36EE64E-8958-479E-AEEC-2E74E08B9F4B

P577

Q36835221-593F6077-B504-4004-A163-C9C84BFAF6AB

P5875

Q36835221-0380E026-782D-4C54-8AF3-A089A9928115

P698

Q36835221-8D24ADC3-DB7C-486A-8C35-8E4CCD852ECC

P921

Q36835221-A6F956F5-9802-4FDD-A4B6-FED7068B1662

P932

Q36835221-F8E0D14A-DA53-4E63-8315-221807F7749E

P356

BLOOD-2008-01-135160

P1433

P1476

Lymphoma depletion during CD20 ...... , FcgammaRIII, and FcgammaRIV.

@en

P2093

Cynthia M Magro

http://www.w3.org/2001/XMLSchema#string

Jonathan C Poe

http://www.w3.org/2001/XMLSchema#string

Karen M Haas

http://www.w3.org/2001/XMLSchema#string

Mayuka Horikawa

http://www.w3.org/2001/XMLSchema#string

Thomas F Tedder

http://www.w3.org/2001/XMLSchema#string

Veronique Minard-Colin

http://www.w3.org/2001/XMLSchema#string

Yan Xiu

http://www.w3.org/2001/XMLSchema#string

Yasuhito Hamaguchi

http://www.w3.org/2001/XMLSchema#string

P2860

Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

IgEb immune complexes activate macrophages through FcgammaRIV binding

FcgammaRIV: a novel FcR with distinct IgG subclass specificity

An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab.

Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease.

Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae.

Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease.

Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors.

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism

P304

1205-1213

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2008-01-135160

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5354259

http://www.w3.org/2001/XMLSchema#string

P698

18495955

http://www.w3.org/2001/XMLSchema#string

P921

P932

2515149

http://www.w3.org/2001/XMLSchema#string